Somewhere in the last 5 years, a quiet divergence opened up between what the science says about human health and what a standard medical check-up actually measures.
That gap is now wide enough to drive a cultural flashpoint through.
And the fitness and wellness industry, not the healthcare system, is the one accelerating it.
The numbers on your cholesterol panel, your BMI and your resting blood pressure have defined clinical health for decades, and their importance has certainly not diminished.
But a growing body of research, much of it now accessible to consumers rather than just clinicians, is establishing that a different set of measurements are also very predictive of whether you’ll still be alive and functional in 20 years.
The problem is that most clinics aren’t measuring them, most health insurers aren’t paying for them, and most patients don’t yet know to ask about them.
That’s changing fast. And the tension it creates is going to be one of the defining friction points in health culture for the next decade.
The Metrics That Actually Predict Lifespan
Start with VO2 max, the measure of how efficiently your body uses oxygen during exercise. Large-scale studies confirm that each one-MET gain in cardiorespiratory fitness reduces all-cause mortality risk by 13 to 15%.
When comparing someone of low fitness to someone of elite fitness, the data shows a fivefold difference in mortality over a decade, a gap larger than the mortality impact of Type 2 diabetes, hypertension, or end-stage renal disease.
Moving from the bottom quartile of cardiorespiratory fitness to the middle is, in mortality terms, comparable to curing a serious chronic disease.
Grip strength tells a similar story.
A 2024 study in Scientific Reports using data from nearly 10,000 adults confirmed the predictive power of grip strength for all-cause mortality across age groups and both sexes. You can measure it with a device that costs less than $50.
Then there’s ApoB, a blood marker that’s been sitting in the research literature for decades while the healthcare system largely continued measuring standard LDL cholesterol instead. ApoB measures the number of harmful fat particles in the blood rather than just the amount of cholesterol they carry, and because it’s a direct count rather than an estimate, it provides a more accurate picture of cardiovascular disease risk. Up to 17.5% of people have dangerously high ApoB levels despite normal cholesterol tests, meaning a significant portion of the population is being told their heart disease risk is low when it isn’t.
Despite data suggesting ApoB measurement outperforms LDL cholesterol in predicting cardiovascular disease risk, it has not become widely adopted into routine clinical practice.
The test is widely available and costs around $60 from major lab providers. The barrier isn’t access. It’s inertia.
Add muscle mass, balance, resting heart rate variability, fasting insulin, and Lp(a) to the list and you have a picture of human health that is measurably more predictive of long-term outcomes than almost anything captured in a standard annual check-up.
A 2022 study published in the British Journal of Sports Medicine found that the ability to balance on one leg for ten seconds predicts survival in middle-aged and older individuals. One leg. Ten seconds… yet most people have never done this test once in a medical setting.
The Knowledge Gap Is Closing on One Side Only
For most of medical history, the information asymmetry between doctor and patient was almost total. The physician knew what the science said. The patient trusted the physician. The system, whatever its flaws, had a clear logic.
That asymmetry is collapsing, and not symmetrically. Consumers are gaining access to longevity science faster than the healthcare system is incorporating it. Podcasts, direct-to-consumer blood testing platforms, wearables, and a new wave of longevity-literate practitioners have put metrics like VO2 max, ApoB, and HOMA-IR into everyday conversation for a significant and growing segment of the population.
Comprehensive testing platforms like Function Health, Superpower, and others now offer large batteries of laboratory tests, often accompanied by imaging, marketed as opportunities to identify vulnerabilities early, with all of them working on AI-enabled data plays that promise some version of personalised recommendation.
These are not fringe products. Function Health, co-founded by longevity physician Mark Hyman, has processed millions of tests. The market for consumer longevity diagnostics is scaling rapidly precisely because it’s serving a need the standard healthcare system is not.
Patients now navigate health through influencers, direct-to-consumer platforms, and AI, often meeting doctors only at the end to manage the fallout, with authority no longer automatically given and doctors needing to reinvent themselves as trusted guides in a fragmented, algorithm-driven health system.
That’s a dramatic reframing of what a medical consultation is for. The patient who arrives with 6 months of continuous glucose monitoring data, a DEXA scan, a VO2 max test, and an ApoB result isn’t looking for a diagnosis. They’re looking for interpretation and action. Many healthcare systems are not set up to provide it.
Why the Healthcare System Is Struggling to Catch Up
The lag isn’t about ignorance… it’s about structure.
Healthcare systems, particularly publicly funded ones, are built around disease treatment rather than health optimisation. The metrics they measure, the ones embedded in insurance reimbursement structures, national guidelines, and clinical training, reflect decades of evidence gathered on sick populations.
VO2 max testing requires equipment and time that a 10 minute doctors appointment doesn’t accommodate. ApoB isn’t on a standard lipid panel because LDL has been the reference point since the 1960s and changing clinical defaults requires a level of consensus-building and guideline revision that moves slowly by design.
Medicine’s conservatism around metrics is partly epistemic, partly structural, and partly the rational self-protection of a profession operating in a high-stakes, heavily regulated environment.
The gap between what the evidence says and what gets measured in a standard appointment is a gap between two different timelines, one of science and one of systems.
The Cultural Flashpoint This Creates
A generation that has grown up optimising everything, their sleep, their macros, their HRV, their running economy, is now applying the same rigour to preventive medicine. They are arriving at healthcare appointments not as supplicants but as informed consumers with their own data, their own frameworks, and often their own hypotheses about what’s going on in their bodies.
This creates friction in both directions.
On one side, the democratisation of longevity science is genuinely valuable. People who know their VO2 max is in the bottom quartile have a powerful, modifiable target. People who discover their ApoB is elevated despite normal LDL can act years before a cardiac event that a standard panel would never have flagged. The information, in the right hands, saves lives.
On the other side, longevity medicine scaled faster than its foundations in recent years, with reach sometimes mattering more than outcomes and patients often hearing influencers before doctors, creating a bottleneck not of innovation but of education, judgment, and clinical standards.
The same consumer longevity ecosystem that surfaces genuinely important biomarkers also sells supplements of dubious merit, promotes unnecessary testing, and creates health anxiety around numbers that, without clinical context, are hard to interpret correctly.
Knowing your ApoB is one thing. Understanding what to do about it, whether lifestyle changes are sufficient or medication is warranted, at what rate it needs to come down and over what timeframe, requires clinical judgment that an app cannot reliably provide.
The patient who arrives well-informed is a gift to a thoughtful clinician and a challenge to an unprepared one. The healthcare system is about to encounter a lot more of both.
The Market That’s Filling the Gap
The opportunity being created here is significant and largely untapped. What’s needed is not more data generation but more sense-making: practitioners who can bridge the longevity science world and the clinical world, translating consumer-level biomarker data into actionable, personalised health plans.
Fitness platforms, wearable companies, and comprehensive testing platforms are all working feverishly on AI-enabled data plays promising some version of personalised recommendation, but the current gap between “here is your result” and “here is what you should do” remains wide. The services that close it credibly, with human expertise layered on top of data, will command both loyalty and premium pricing.
The clinician who adds VO2 max testing, ApoB measurement, and grip strength assessment to their standard protocol isn’t just offering better medicine. They’re offering a differentiated service to a patient population that has already decided these metrics matter and is currently paying for them elsewhere.
New practitioner categories are emerging to fill the space: longevity physicians, health coaches with clinical literacy, performance-oriented physiotherapists, and metabolic health specialists who sit between the gym and the hospital. None of them existed as defined roles 15 years ago. All of them are in high demand now.
Bottom Line
The longevity science reckoning is not really about which metrics are better. It’s about who controls the definition of health, and what that definition is for.
The healthcare system’s definition has historically been the absence of disease: you’re healthy until you’re sick, at which point treatment begins. The longevity movement’s definition is something different: health as a set of measurable capacities that can be actively built, tracked, and protected decades before disease arrives.
These are not just different metrics. They are different philosophies.
The tension between them is only going to intensify as the consumer longevity ecosystem grows, as wearables get more sophisticated, as direct-to-consumer testing becomes cheaper and more comprehensive, and as a generation of wellness-native consumers ages into the demographic that most frequently interacts with healthcare.